Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 2025: 10-Year Mortality in NOBLE: PCI vs CABG for Left Main Disease
Author(s): Evald Høj Christiansen Added: 4 months ago
TCT 2025 - 10-year findings from NOBLE showed no safety concerns for percutaneous coronary intervention (PCI) compared to coronary artery bypass surgery (CABG) for the treatment of left main coronary artery (LMCA) disease.Dr Evald Høj Christiansen (Aarhus University Hospital, Aarhus, DK) joins us to share the 10-year mortality findings from the NOBLE trial, investigating PCI vs CABG in LMCA… View more

Intervention

Prevention & Chronic Conditions
Left Main Percutaneous Coronary Revascularization
Author(s): Mirvat Alasnag , Khalid Al Johani , Added: 2 years ago
In this episode of the Radcliffe Podcast, we are joined by Dr Mirvat Alasnag (King Fahd Armed Forces Hospital, SA), Dr Khalid AlJohani (King Saud University, SA), and Dr Abdulrahman AlMoghairi (Prince Sultan Cardiac Center, SA) as they discuss methods and approaches to left main percutaneous coronary revascularization. In this podcast, Dr Alasnag, Dr AlJohani and Dr AlMoghairi discuss the… View more

Intervention
Left Atrial Myxoma
Author(s): Preet Shaikh , Mario Rodriguez Rivera , Michael A Beal , et al Added: 1 year ago

Heart Failure

Prevention & Chronic Conditions
Early Ventricular Septal Rupture following Acute Myocardial Infarction Diagnosed on Left Ventriculogram
Author(s): Arpanjeet Kaur , Yash Patel , Jacqueline Tamis-Holland Added: 1 year ago

Imaging & Diagnostics

MI/ACS
ESC 25 Discussion: 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
Author(s): Harriette Van Spall , Michael Andrew Borger Added: 5 months ago
ESC Congress 2025 - Dr Harriette Van Spall (McMaster University, Canada) sits down with Professor Michael Borger (University of Leipzig Heart Center, Germany), Co-Chair of the newly released 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease.The new guidelines bring together the latest evidence and expert consensus on how to diagnose, evaluate, and treat patients with valvular… View more

Guidelines & Statements

Imaging & Diagnostics
TMVR in Patients with Multivalvular Heart Disease with Dr Kimberly Holst
Author(s): Kimberly Holst Added: 4 months ago
Navigate the strategic complexities of transcatheter mitral valve replacement in multivalvular disease with Dr Kimberly HolstThis presentation, part of Women As One's comprehensive Structural Interventions track, provides a systematic framework for approaching multivalvular heart disease. The presentation establishes the foundational principle of strategic intervention sequencing in high-risk… View more

Intervention
Secondary Prevention of Atherosclerotic Cardiovascular Disease
Author(s): Madelyn Hurwitz , Olayinka J Agboola , Abhishek Gami , et al Added: 10 months ago

Prevention & Chronic Conditions
ESC 25 Guidelines Discussion: Management of Cardiovascular Disease and Pregnancy
Author(s): Harriette Van Spall , Julie De Backer Added: 5 months ago
ESC Congress 2025 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) joins Prof Julie De Backer (University Hospital Ghent, BE) to discuss the newly released 2025 ESC Guidelines for the Management of Cardiovascular Disease in Pregnancy. Together, they highlight key updates, critical advances in maternal cardiovascular care, and evidence-based recommendations tailored for this… View more

CV Disease in Special Populations

Guidelines & Statements
ERA 25: Albuminuria, eGFR Dip and Disease Severity & Empagliflozin
Author(s): William Herrington Added: 8 months ago
ERA 2025 - Findings from a meta-analysis of chronic kidney disease outcomes in patients treated with empagliflozin suggest that people with CKD benefit from the drug irrespective of diabetes of albuminuria status.ProfWilliam Herrington (University of Oxford, Oxford, UK) joins us to discuss outcomes from an individual patient-level data meta-analysis, investigating the impact of diabetes,… View more

Cardiovascular Renal Metabolic
ERA 25: eGFR Dips and Disease Severity on Empagliflozin
Author(s): Added: 9 months ago
ERA 2025 - Results from a meta-analysis of trials including EMPA-KIDNEY show the treatment effect of empagliflozin is not modified by level of predicted acute eGFR dip.Dr Natalie Staplin (University of Oxford, Oxford, UK) joins us to discuss findings from a meta-analysis of four trials, including the EMPA-KIDNEY trial (NCT03594110), investigating the impact of acute eGFR dips and markers of… View more

Cardiovascular Renal Metabolic